BSX

Boston ScientificC

NYSE / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$56.00

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$45.00

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$32.00

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-02

AI commentary

News tone is negative following the guidance warning and Citi downgrade, despite the company's reported operational restoration and favorable forensic update. The packet's September 14 article said shares were down 6.4% since Q2 results, but no verified immediate post-cyber or post-October-release price reaction is available; the October 1 price anchor is $43.23. Social, options, short-interest and employee measures were not supplied, so their zero placeholders are unavailable data, not neutral readings. The deterministic prior is positive, but the subsequent primary-source cyber disclosure materially weakens near-term confidence.

RankAlpha Sentiment Codex - 2026-10-02

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-10-28eventOctober 28 outlook reset after cyber disruptionMedium impact

Boston Scientific said the August 25 incident disrupted manufacturing and order fulfillment, is likely to materially affect Q3 and full-year results, and makes its July sales-growth and adjusted-EPS guidance unlikely to be met. It plans to update its outlook on October 28. The size of the shortfall and recoverable backlog are the key unknowns. [#SEC-8K-2026-09-08] SEC filing

2026-10-28catalystOperational recovery and backlog conversionMedium impact

The company reported that manufacturing, order fulfillment and shipping were restored, while its September 22 update reported no evidence of ongoing threat activity after containment. Restored operations do not establish how much deferred revenue will be recovered; order conversion remains the near-term test. [#SEC-8K-2026-09-08] [#PR-2026-09-22] Company update

2027-01-01eventMedSurg and Asia-Pacific leadership transitionMedium impact

Arthur Butcher is scheduled to retire as group president of MedSurg and Asia Pacific effective January 1, 2027. The filing does not identify a successor; transition execution merits monitoring rather than an assumed operating impact. [#8-K-2026-09-23] SEC filing

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-02 • Updated nightlySource: Internal modelMethodology